Neratinib, Free Base

Neratinib, Free Base
Artikelnummer Größe Datenblatt Manual SDB Lieferzeit Menge Preis
LC-N-6404_100mg 100 mg - -

3 - 15 Werktage*

175,00 €
LC-N-6404_200mg 200 mg - -

3 - 15 Werktage*

249,00 €
LC-N-6404_500mg 500 mg - -

3 - 15 Werktage*

340,00 €
LC-N-6404_1g 1 g - -

3 - 15 Werktage*

486,00 €
LC-N-6404_2g 2 g -

3 - 15 Werktage*

720,00 €
LC-N-6404_5g 5 g -

3 - 15 Werktage*

1.329,00 €
LC-N-6404_10g 10 g -

3 - 15 Werktage*

1.954,00 €
 
Solubility: Soluble in DMSO at 2 mg/mL with warming, very poorly soluble in ethanol, very poorly... mehr
Produktinformationen "Neratinib, Free Base"
Solubility: Soluble in DMSO at 2 mg/mL with warming, very poorly soluble in ethanol, very poorly soluble in water, maximum solubility in plain water is estimated to be about 5-20 µM, buffers, serum, or other additives may increase or decrease the aqueous solubility. Neratinib, also known as HKI-272, is considered to be a second-generation inhibitor of the ErbB family of receptor kinases. Sequist, L.V., et al. 'Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.' Oncologist 12: 325-330 (2007). Neratinib is an irreversible inhibitor of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2) tyrosine kinases by targeting a cysteine residue in the ATP-binding site of the receptor. Rabindran, S.K., et al. 'Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.' Cancer Res. 64: 3958-3965 (2004). Neratinib inhibits the proliferation of HER-2 overexpressing human breast cancer cell lines and EGFR-dependent cells in vitro. In vivo, neratinib is active against HER-2- and EGFR-dependent tumor xenograft models. Rabindran, S.K., et al. 'Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.' Cancer Res. 64: 3958-3965 (2004). Acquired resistance of non-small cell lung cancers to gefitinib because of a T790M mutation in the EGFR kinase domain is circumvented by neratinib. Kwak, E.L., et al. 'Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.' Proc. Natl. Acad. Sci. USA 102: 7665-7670 (2005). Neratinib is active against HER-2-positive breast cancer in patients. Wong, K.K., et al. 'HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors.' J. Clin. Oncol. 24: 3018 (2006).
Schlagworte: HKI-272
Hersteller: LC Laboratories
Hersteller-Nr: N-6404

Eigenschaften

Anwendung: EGFR/ ERBB2 inhibitor
MW: 557,04 D
Formel: C30H29ClN6O3
Reinheit: >99%

Datenbank Information

CAS : 698387-09-6| Passende Produkte
KEGG ID : K04361 | Passende Produkte

Handhabung & Sicherheit

Lagerung: -20°C
Versand: +20°C (International: °C)
Signalwort: Warning
GHS-Piktogramme:
H-Sätze: H335, H361, H303, H313, H333
P-Sätze: P261, P264, P280, P314, P308+P311, P501
Achtung
Nur für Forschungszwecke und Laboruntersuchungen: Nicht für die Anwendung im oder am Menschen!
Hier kriegen Sie ein Zertifikat
oder , um Analysenzertifikate anzufordern.
Bewertungen lesen, schreiben und diskutieren... mehr
Kundenbewertungen für "Neratinib, Free Base"
Bewertung schreiben
oder , um eine Produktbewertung abzugeben.
Zuletzt angesehen